Literature DB >> 21903243

Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma.

Simon P Kim1, Christopher J Weight, Bradley C Leibovich, R Houston Thompson, Brian A Costello, John C Cheville, Christine M Lohse, Stephen A Boorjian.   

Abstract

OBJECTIVE: To characterize the incidence and clinicopathologic factors associated with late recurrence after surgical resection for renal cell carcinoma (RCC) because the recurrence patterns >5 years after nephrectomy have been poorly described.
METHODS: We identified 1454 patients treated with nephrectomy for localized RCC from 1970 to 2000 who had remained free of disease for 5 years. Subsequent tumor recurrence was classified as renal recurrence and distant metastasis. The incidence of recurrence >5 years from surgery was estimated using the Kaplan-Meier method. The associations of clinicopathologic variables with late recurrence were analyzed using Cox proportional hazard regression models.
RESULTS: With a median postoperative follow-up of 13.9 years (range 5.1-38.9), 63 patients (4.3%) experienced late renal recurrence at a median of 9.3 years (range 5.1-25.3), and 172 patients (11.8%) developed late distant metastases at a median of 9.6 years (range 5.1-26.6) after surgery. The estimated recurrence-free survival rate at 10 and 15 years was 97.3% and 95.2% for renal recurrence, and 93.1% and 85.9% for distant metastases, respectively. On multivariate analysis, increased tumor size (hazard ratio [HR] 1.12; P < .001) was associated with late renal tumor recurrence, and increased tumor size (HR 1.07; P = .018), clear cell or collecting duct histologic features (HR 3.76; P < .001), and tumor Stage pT1b (HR 2.8; P < .001), pT2a (HR 4.5; P < .001), pT2b (HR 3.4; P = .007), and pT3-pT4 (HR 5.1; P < .001) were associated with distant metastasis.
CONCLUSION: After an initial 5-year postoperative disease-free interval, approximately 5% and 15% of patients will develop renal recurrence and distant metastases, respectively, during the next decade. Therefore, long-term surveillance remains necessary after nephrectomy. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21903243     DOI: 10.1016/j.urology.2011.05.012

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  30 in total

1.  Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Authors:  Wassim Kassouf; Leonardo L Monteiro; Darrel E Drachenberg; Adrian S Fairey; Antonio Finelli; Anil Kapoor; Jean-Baptiste Lattouf; Michael J Leveridge; Nicholas E Power; Frederic Pouliot; Ricardo A Rendon; Robert Sabbagh; Alan I So; Simon Tanguay; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2018-05-31       Impact factor: 1.862

2.  Impact of routine imaging in the diagnosis of recurrence for patients with localized and locally advanced renal tumor treated with nephrectomy.

Authors:  Baptiste Gires; Zine-Eddine Khene; Pierre Bigot; Quentin Alimi; Benoit Peyronnet; Grégory Verhoest; Andrea Manunta; Karim Bensalah; Romain Mathieu
Journal:  World J Urol       Date:  2019-03-20       Impact factor: 4.226

3.  Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines.

Authors:  Suzanne B Stewart; R Houston Thompson; Sarah P Psutka; John C Cheville; Christine M Lohse; Stephen A Boorjian; Bradley C Leibovich
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

Review 4.  [Why have tyrosine kinase inhibitors failed in the adjuvant situation and do checkpoint inhibitors make more sense?]

Authors:  Susanne Krege
Journal:  Urologe A       Date:  2020-02       Impact factor: 0.639

5.  Ovarian metastasis of clear cell renal cell carcinoma: A case report.

Authors:  Lenka Bauerová; Pavel Dundr; Daniela Fischerová; Michael Pešl; Michal Zikán; Andrea Burgetová
Journal:  Can Urol Assoc J       Date:  2014 Mar-Apr       Impact factor: 1.862

Review 6.  Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.

Authors:  Andrew T Lenis; Nicholas M Donin; David C Johnson; Izak Faiena; Amirali Salmasi; Alexandra Drakaki; Arie Belldegrun; Allan Pantuck; Karim Chamie
Journal:  J Urol       Date:  2017-05-04       Impact factor: 7.450

7.  Factors affecting the time to recurrence after radical nephrectomy for localized renal cell carcinoma.

Authors:  Hee-Seo Son; Seung Hyun Jeon; Sung-Goo Chang
Journal:  Korean J Urol       Date:  2013-11-06

8.  The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma.

Authors:  Tim J van Oostenbrugge; Stephanie G C Kroeze; J L H Ruud Bosch; Harm H E van Melick
Journal:  World J Urol       Date:  2014-09-02       Impact factor: 4.226

9.  New tools for assessing the individual risk of metastasis in renal cell carcinoma.

Authors:  Edwin Herrmann; Carsten Weishaupt; Birgit Pöppelmann; Carina Hillgruber; Gerald Pühse; Laura Maria Krabbe; Micha Feld; Martin Steinhoff; Tobias Goerge
Journal:  Clin Exp Metastasis       Date:  2012-08-23       Impact factor: 5.150

Review 10.  Follow-up after curative treatment of localised renal cell carcinoma.

Authors:  Saeed Dabestani; Lorenzo Marconi; Teele Kuusk; Axel Bex
Journal:  World J Urol       Date:  2018-05-16       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.